Hyderabad: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) (“NATCO”) hereby informs you that the U.S. Food and Drug Administration (FDA) had conducted an inspection at the Active Pharmaceutical Ingredient Division located in Manali, Chennai from November 17th – November 21st, 2025. The Company received seven (7) observation in the Form-483.
We hereby notify that the Company has received the EIR (Establishment Inspection Report) from the USFDA on the classification of the above-referred inspection as Voluntary Action Indicated (VAI).
